These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

576 related articles for article (PubMed ID: 26245900)

  • 1. The Mutant KRAS Gene Up-regulates BCL-XL Protein via STAT3 to Confer Apoptosis Resistance That Is Reversed by BIM Protein Induction and BCL-XL Antagonism.
    Zaanan A; Okamoto K; Kawakami H; Khazaie K; Huang S; Sinicrope FA
    J Biol Chem; 2015 Sep; 290(39):23838-49. PubMed ID: 26245900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversal of Mutant KRAS-Mediated Apoptosis Resistance by Concurrent Noxa/Bik Induction and Bcl-2/Bcl-xL Antagonism in Colon Cancer Cells.
    Okamoto K; Zaanan A; Kawakami H; Huang S; Sinicrope FA
    Mol Cancer Res; 2015 Apr; 13(4):659-69. PubMed ID: 25548100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism.
    Rahmani M; Aust MM; Attkisson E; Williams DC; Ferreira-Gonzalez A; Grant S
    Cancer Res; 2013 Feb; 73(4):1340-51. PubMed ID: 23243017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Failure to induce apoptosis via BCL-2 family proteins underlies lack of efficacy of combined MEK and PI3K inhibitors for KRAS-mutant lung cancers.
    Hata AN; Yeo A; Faber AC; Lifshits E; Chen Z; Cheng KA; Walton Z; Sarosiek KA; Letai A; Heist RS; Mino-Kenudson M; Wong KK; Engelman JA
    Cancer Res; 2014 Jun; 74(11):3146-56. PubMed ID: 24675361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of HSP90 by AUY922 Preferentially Kills Mutant KRAS Colon Cancer Cells by Activating Bim through ER Stress.
    Wang CY; Guo ST; Wang JY; Liu F; Zhang YY; Yari H; Yan XG; Jin L; Zhang XD; Jiang CC
    Mol Cancer Ther; 2016 Mar; 15(3):448-59. PubMed ID: 26832792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Up-regulation of pro-apoptotic protein Bim and down-regulation of anti-apoptotic protein Mcl-1 cooperatively mediate enhanced tumor cell death induced by the combination of ERK kinase (MEK) inhibitor and microtubule inhibitor.
    Kawabata T; Tanimura S; Asai K; Kawasaki R; Matsumaru Y; Kohno M
    J Biol Chem; 2012 Mar; 287(13):10289-10300. PubMed ID: 22270368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic activity and heterogeneous acquired resistance of combined MDM2 and MEK inhibition in KRAS mutant cancers.
    Hata AN; Rowley S; Archibald HL; Gomez-Caraballo M; Siddiqui FM; Ji F; Jung J; Light M; Lee JS; Debussche L; Sidhu S; Sadreyev RI; Watters J; Engelman JA
    Oncogene; 2017 Nov; 36(47):6581-6591. PubMed ID: 28783173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MEK1/2 inhibitors potentiate UCN-01 lethality in human multiple myeloma cells through a Bim-dependent mechanism.
    Pei XY; Dai Y; Tenorio S; Lu J; Harada H; Dent P; Grant S
    Blood; 2007 Sep; 110(6):2092-101. PubMed ID: 17540843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutant BRAF Upregulates MCL-1 to Confer Apoptosis Resistance that Is Reversed by MCL-1 Antagonism and Cobimetinib in Colorectal Cancer.
    Kawakami H; Huang S; Pal K; Dutta SK; Mukhopadhyay D; Sinicrope FA
    Mol Cancer Ther; 2016 Dec; 15(12):3015-3027. PubMed ID: 27765849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of ERK-BIM and STAT3-survivin signaling pathways in ALK inhibitor-induced apoptosis in EML4-ALK-positive lung cancer.
    Takezawa K; Okamoto I; Nishio K; Jänne PA; Nakagawa K
    Clin Cancer Res; 2011 Apr; 17(8):2140-8. PubMed ID: 21415216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined MEK and BCL-2/X
    Iavarone C; Zervantonakis IK; Selfors LM; Palakurthi S; Liu JF; Drapkin R; Matulonis UA; Hallberg D; Velculescu VE; Leverson JD; Sampath D; Mills GB; Brugge JS
    Mol Cancer Ther; 2019 Mar; 18(3):642-655. PubMed ID: 30679390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Bcl-2 homology domain 3 (BH3)-only proteins Bim and bid are functionally active and restrained by anti-apoptotic Bcl-2 family proteins in healthy liver.
    Kodama T; Hikita H; Kawaguchi T; Saito Y; Tanaka S; Shigekawa M; Shimizu S; Li W; Miyagi T; Kanto T; Hiramatsu N; Tatsumi T; Takehara T
    J Biol Chem; 2013 Oct; 288(42):30009-30018. PubMed ID: 23986435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic.
    Cragg MS; Jansen ES; Cook M; Harris C; Strasser A; Scott CL
    J Clin Invest; 2008 Nov; 118(11):3651-9. PubMed ID: 18949058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies.
    Choudhary GS; Al-Harbi S; Mazumder S; Hill BT; Smith MR; Bodo J; Hsi ED; Almasan A
    Cell Death Dis; 2015 Jan; 6(1):e1593. PubMed ID: 25590803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erythropoietin-induced phosphorylation/degradation of BIM contributes to survival of erythroid cells.
    Abutin RM; Chen J; Lung TK; Lloyd JA; Sawyer ST; Harada H
    Exp Hematol; 2009 Feb; 37(2):151-8. PubMed ID: 19100675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PI3K/mTOR dual inhibitor NVP-BEZ235 decreases Mcl-1 expression and sensitizes ovarian carcinoma cells to Bcl-xL-targeting strategies, provided that Bim expression is induced.
    Jebahi A; Villedieu M; Pétigny-Lechartier C; Brotin E; Louis MH; Abeilard E; Giffard F; Guercio M; Briand M; Gauduchon P; Lheureux S; Poulain L
    Cancer Lett; 2014 Jun; 348(1-2):38-49. PubMed ID: 24650799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IL-10/Janus kinase/signal transducer and activator of transcription 3 signaling dysregulates Bim expression in autoimmune lymphoproliferative syndrome.
    Niss O; Sholl A; Bleesing JJ; Hildeman DA
    J Allergy Clin Immunol; 2015 Mar; 135(3):762-70. PubMed ID: 25174872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bcl-2/Bcl-xL inhibition increases the efficacy of MEK inhibition alone and in combination with PI3 kinase inhibition in lung and pancreatic tumor models.
    Tan N; Wong M; Nannini MA; Hong R; Lee LB; Price S; Williams K; Savy PP; Yue P; Sampath D; Settleman J; Fairbrother WJ; Belmont LD
    Mol Cancer Ther; 2013 Jun; 12(6):853-64. PubMed ID: 23475955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutant B-RAF mediates resistance to anoikis via Bad and Bim.
    Boisvert-Adamo K; Aplin AE
    Oncogene; 2008 May; 27(23):3301-12. PubMed ID: 18246127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FTY720 induces apoptosis of chronic myelogenous leukemia cells via dual activation of BIM and BID and overcomes various types of resistance to tyrosine kinase inhibitors.
    Kiyota M; Kuroda J; Yamamoto-Sugitani M; Shimura Y; Nakayama R; Nagoshi H; Mizutani S; Chinen Y; Sasaki N; Sakamoto N; Kobayashi T; Matsumoto Y; Horiike S; Taniwaki M
    Apoptosis; 2013 Nov; 18(11):1437-1446. PubMed ID: 23851982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.